COMBINATION VACCINE/MICROBICIDE EFFICACY ASSESSMENT IN THE SHIV/MACAQUE MODEL

$61,801P51FY2010RRNIH

Tulane University Of Louisiana, New Orleans LA

Investigators

Linked publications, trials & patents

Paper 38091409 Paper 36890518 Paper 36678479 Paper 36096938 Paper 35333631 Paper 35281029 Paper 35148813 Paper 34954656 Paper 33771926 Paper 31431806 Paper 31398085 Paper 31119711 Paper 31114576 Paper 30830861 Paper 30617987 Paper 30404798 Paper 30260764 Paper 30040479 Paper 29514950 Paper 29504290 Paper 29437924 Paper 29408631 Paper 29343566 Paper 29132995 Paper 28558791 Paper 28381571 Paper 28153013 Paper 27834864 Paper 27792681 Paper 27605560 Paper 27552154 Paper 27466784 Paper 27430034 Paper 27391120 Paper 27273075 Paper 26937033 Paper 26851132 Paper 26796229 Paper 26790502 Paper 26714480 Paper 26700298 Paper 26699868 Paper 26647718 Paper 26607731 Paper 26588868 Paper 26539878 Paper 26432896 Paper 26419894 Paper 26365904 Paper 26336283 Paper 26242703 Paper 26178993 Paper 26052540 Paper 25960611 Paper 25956030 Paper 25943275 Paper 25892509 Paper 25889406 Paper 25730547 Paper 25639184 Paper 25635151 Paper 25591175 Paper 25452565 Paper 25378491 Paper 25360552 Paper 25322074 Paper 25257285 Paper 25232870 Paper 25197327 Paper 25165491 Paper 25165117 Paper 25164280 Paper 25143472 Paper 25138734 Paper 25092823 Paper 25055842 Paper 25024382 Paper 25024365 Paper 24981450 Paper 24970236 Paper 24962586 Paper 24956211 Paper 24758934 Paper 24743303 Paper 24740100 Paper 24549971 Paper 24534529 Paper 24524407 Paper 24517274 Paper 24490123 Paper 24464410 Paper 24272803 Paper 24266615 Paper 24157855 Paper 24117013 Paper 24114360 Paper 24109219 Paper 24105901 Patent 6660274 Patent 6475492

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We completed repeat IVAG challenge of the eight DNA/Ad5 SIV gag-pol vaccinated and eight unvaccinated female Indian rhesus macaques (RM). We modified the challenge protocol as follows to assure that 100% of the unvaccinated macaques will be infected: 10 challenges with 300 TCID50, 5 challenges with 1000 TCID50 and 5 challenges with 3000 TCID50 of cell-free SHIVSF162P3 for a total of 20 exposures. Using this escalated dose challenge protocol, all 8 macaques in the control unvaccinated group were infected, with a range of 3-18 exposures needed to establish systemic infection. Six of the eight vaccinated macaques were also infected, with 1-17 inoculations needed for infection, while two remained uninfected after 20 exposures. Analysis of the cumulative proportion of uninfected macaques as a function of the number of weekly intravaginal exposures showed that the survival curve for the vaccinated group shifted to the left of the control curve from the 1st to 3rd exposure, reflecting the fact that two of the vaccinated macaques were infected after 1 and 2 virus exposures, whereas a minimum of three exposures was required to infect animals in the unvaccinated group. The vaccine survival curve diverged from that of the control after the 5th exposure, becoming maximal from the 9th to the 16th exposure. This latter observation, together with the fact the 2 of the 8 vaccinated macaques remained uninfected after 20 challenges is suggestive of a "leaky vaccine" effect.

View original record on NIH RePORTER →